StockNews.AI
FBLG
StockNews.AI
37 days

FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates

1. FibroBiologics presents at the BIO CEO Investor Conference in February 2025. 2. CEO and key management will discuss fibroblast-based therapeutic strategies. 3. The company holds over 160 patents in chronic disease treatments. 4. FibroBiologics aims for advancements in chronic disease therapies via innovative cell technology.

4 mins saved
Full Article

FAQ

Why Bullish?

The presentation demonstrates ongoing commitment to research that may enhance investor confidence, similar to successful biotech showcases in the past.

How important is it?

The article details significant corporate activities that directly relate to FibroBiologics' strategic direction.

Why Short Term?

Immediate reactions may occur around the conference dates as investors react to new information.

Related Companies

FBLG
FibroBiologics to also present at the BIO CEO & Investor Conference February 05, 2025 09:15 ET  | Source: Fibrobiologics, Inc. HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it will host an in-person analyst day at the New York Marriott Marquis on February 12, 2025, at 2:00 p.m. ET. The event will feature presentations from the following members of the Company's management: Pete O’Heeron, Chief Executive OfficerHamid Khoja, PhD, Chief Scientific OfficerRobert Hoffman, Interim Chief Financial Officer The event will highlight FibroBiologics’ research and development strategy for advancing fibroblast-based therapeutics to address chronic diseases. A live Q&A session will follow the formal presentations. An audio recording of the presentation and Q&A will be available under the investor section of the FibroBiologics website after the event. In addition, FibroBiologics will be presenting at the 2025 BIO CEO & Investor Conference in New York, NY, from February 10-11. Details of the event are as follows: Date: Tuesday, February 11Time: 11:15 a.m. ETLocation: The New York Marriott MarquisTrack: Plymouth Room To learn more about the event, please visit https://bcic.bio.org/, or to schedule one-on-one meetings, please email FibroBiologicsIR@russopr.com. About FibroBiologics Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com. General Inquiries:info@fibrobiologics.com Investor Relations:Nic Johnson Russo Partners(212) 845-4242fibrobiologicsIR@russopr.com Media Contact:Liz PhillipsRusso Partners(347) 956-7697Elizabeth.phillips@russopartnersllc.com

Related News